Clinical trial
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
NCT00119730 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00119730 |
|---|---|
| Title | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma |
| Official title | Abbreviated Fludarabine / Mitoxantrone / Rituximab Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Fludarabine, Mitoxantrone, Rituximab, Zevalin |
| Enrollment | 30 |
| Start date | Feb 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2013 |
| First posted | Jul 14, 2005 |
| Last update posted | Apr 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: